MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41433-024-03275-y

Медицинская библиотека · Eye (London, England) · 2024

Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study.

Sharma Ashish, Wakabayashi Taku, Regillo Carl D, Cheung Chui Ming Gemmy, Loewenstein Anat, Zur Dinah, Goldberg Dafna, Hilely Assaf, Ozdek Sengul, Özdemir Hüseyin Baran, Parachuri Nikulaa, Kumar Nilesh, Kuppermann Baruch D, Bandello Francesco, Querques Giuseppe

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: To understand subfoveal neurosensory detachment flattening and observe (SNF-Ob) strategy and its relationship with visual acuity in the management of centre-involved diabetic macular oedema (Ci-DMO).

METHODS

This was a multicentric retrospective observational study. We reviewed data of 188 eyes of 130 patients who presented with Ci-DMO with subfoveal neurosensory detachment (NSD) and treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents or steroids. The primary outcome was best corrected visual acuity (BCVA) measured at the time of the first subfoveal neurosensory detachment flattening (SNF) and at the end of follow-up.

RESULTS

Eyes that achieved 20/50 (LogMAR = 0.40) or better at first SNF had mean LogMAR BCVA 0.38 ± 0.21, 0.24 ± 0.11 and 0.21 ± 0.15 at baseline, at the time of first SNF, and at the end of the last follow-up respectively. Mean LogMAR BCVA significantly improved from baseline to first SNF (p < 0.0001; 95% CI 0.115-0.183) and at the end of the last follow-up (p < 0.0001; 95% CI 0.126-0.213) with a change of Early Treatment Diabetic Retinopathy Study (ETDRS) 10 letters. There was no significant difference in improvement in BCVA from the first SNF and at the end of the last follow-up (p = 0.0781; 95% CI -0.002 to 0.046).

CONCLUSIONS

Eyes presenting with Ci-DMO and subfoveal NSD are unlikely to improve at SNF with BCVA > 20/50 (LogMAR = 0.40). Further evidence is needed before the combination of good BCVA and SNF may be considered as endpoint of pharmacological therapy for DMO.

Для цитирования: Sharma Ashish, Wakabayashi Taku, Regillo Carl D, Cheung Chui Ming Gemmy, Loewenstein Anat, Zur Dinah, Goldberg Dafna, Hilely Assaf, Ozdek Sengul, Özdemir Hüseyin Baran, Parachuri Nikulaa, Kumar Nilesh, Kuppermann Baruch D, Bandello Francesco, Querques Giuseppe. Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study.. Eye (London, England). 2024. DOI: 10.1038/s41433-024-03275-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.